Mandelic Acid

Mandelic Acid

SCHEMBL7303720

O=C(NC[C@@H]1CCCNC1)c1ccccc1.O=C(O)[C@H](O)c1ccccc1

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.50
CHEK1 O14757 2/20 0.48
PBK Q96KB5 6/20 0.47
NAMPT P43490 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
ACP1 P24666 1/20 0.44
HPGD P15428 1/20 0.43
CHRM2 P08172 1/20 0.42
CHRM3 P20309 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
SMYD3 Q9H7B4 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mandelic Acid SCHEMBL8716949 1.00 KMT2A (0.50) KMT2ACHEK1PBKNAMPTSMN1; SMN2
Mandelic Acid SCHEMBL7303904 1.00 KMT2A (0.50) KMT2ACHEK1PBKNAMPTSMN1; SMN2
Mandelic Acid SCHEMBL7297870 1.00 KMT2A (0.50) KMT2ACHEK1PBKNAMPTSMN1; SMN2
Mandelic Acid SCHEMBL8716945 1.00 KMT2A (0.50) KMT2ACHEK1PBKNAMPTSMN1; SMN2
SCHEMBL8719970 0.89 KMT2A (0.60) KMT2ACHEK1PBKNAMPTSMN1; SMN2
SCHEMBL2423748 0.89 KMT2A (0.60) KMT2ACHEK1PBKNAMPTSMN1; SMN2
SCHEMBL8719751 0.89 KMT2A (0.60) KMT2ACHEK1PBKNAMPTSMN1; SMN2
SCHEMBL13325386 0.81 NAMPT (0.63) KMT2ANAMPTSMN1; SMN2ACP1HPGD
SCHEMBL5094284 0.81 NAMPT (0.63) KMT2ANAMPTSMN1; SMN2ACP1HPGD
SCHEMBL13325381 0.81 NAMPT (0.63) KMT2ANAMPTSMN1; SMN2ACP1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0559046-B1 N-amidinopiperidinyl(3/4)- or N-amidino-1,4-Oxazinyl(2)-substituted sulfonamides, process for their preparation and use as thrombin inhibitors HOFFMANN LA ROCHE (CH) 2001-07-11 EP disclosed
EP-0559046-A1 N-amidinopiperidinyl(3/4)- or N-amidino-1,4-Oxazinyl(2)-substituted sulfonamides, process for their preparation and use as thrombin inhibitors F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT (CH) 1993-09-08 EP disclosed